NewLink Genetics Corp (NLNK) Upgraded by ValuEngine to Sell
NewLink Genetics Corp (NASDAQ:NLNK) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Thursday.
Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research raised NewLink Genetics Corp from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Wednesday, June 7th. Cantor Fitzgerald set a $32.00 target price on NewLink Genetics Corp and gave the stock a “buy” rating in a research note on Sunday, June 4th. Jefferies Group LLC reissued a “hold” rating and set a $7.00 target price on shares of NewLink Genetics Corp in a research note on Friday, July 14th. Finally, Robert W. Baird cut NewLink Genetics Corp from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $25.00 to $8.00 in a research note on Thursday, June 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. NewLink Genetics Corp presently has an average rating of “Hold” and an average price target of $18.17.
Shares of NewLink Genetics Corp (NASDAQ:NLNK) traded up 74.58% during trading on Thursday, hitting $13.60. The stock had a trading volume of 28,847,710 shares. The firm’s 50-day moving average is $7.21 and its 200 day moving average is $12.81. NewLink Genetics Corp has a 52-week low of $5.90 and a 52-week high of $25.17. The firm’s market cap is $400.13 million.
NewLink Genetics Corp (NASDAQ:NLNK) last posted its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.21. The company had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corp had a negative return on equity of 61.84% and a negative net margin of 161.29%. On average, analysts expect that NewLink Genetics Corp will post ($2.82) EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its position in shares of NewLink Genetics Corp by 3.0% during the first quarter. Wells Fargo & Company MN now owns 162,926 shares of the biotechnology company’s stock worth $3,926,000 after buying an additional 4,701 shares during the period. Driehaus Capital Management LLC purchased a new position in shares of NewLink Genetics Corp during the first quarter worth $5,127,000. Northwest Wealth Management LLC boosted its position in shares of NewLink Genetics Corp by 3.1% during the second quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock worth $426,000 after buying an additional 1,740 shares during the period. Teachers Advisors LLC boosted its position in shares of NewLink Genetics Corp by 2.8% during the fourth quarter. Teachers Advisors LLC now owns 201,807 shares of the biotechnology company’s stock worth $2,075,000 after buying an additional 5,500 shares during the period. Finally, Prudential Financial Inc. purchased a new position in shares of NewLink Genetics Corp during the first quarter worth $443,000. Institutional investors and hedge funds own 54.78% of the company’s stock.
NewLink Genetics Corp Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with MarketBeat.com's FREE daily email newsletter.